Cleveland Clinic nets federal funds for research facility revamp
The Taussig Cancer Institute at the Cleveland Clinic has been awarded more than $2 million from the American Recovery and Reinvestment Act for the renovation and expansion of its translational cancer research facilities. The National Center for Research Resources, which is part of NIH, awarded the grant.
DEREK RAGHAVEN, MD, PHD
The Taussig Cancer Institute at the Cleveland Clinic has been awarded more than $2 million from the American Recovery and Reinvestment Act for the renovation and expansion of its translational cancer research facilities. The National Center for Research Resources, which is part of NIH, awarded the grant.
The funds will be used to update 3,600 square feet of laboratory space that was built on the clinic's main campus in 1928. The space was last renovated in the 1950s. Renovations will include a shared instrumentation room that will free up an additional 500 square feet to allow for more bench research.
The expanded laboratory area also will allow for the recruitment of up to four new independent researchers, a dozen technical support positions, and an administrative assistant.
"The expansion of our translational cancer research capabilities is essential to the mission of the Taussig Cancer Institute," said Derek Raghavan, MD, PhD, chair of the institute, in a written statement. "This award will allow us to continue to bring the latest research straight from the lab to the bedside to aid in the diagnosis and treatment of patients."
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
